top of page
News
May 10 2022 - CARLSBAD, CA
Amicrobe Selects Clinical Formulation for Amicidin-α PFC, Supported by Department of Defense for Prolonged Field Care of Injured Warfighters
April 26, 2022 - CARLSBAD, CA
Amicrobe, Inc., Developer of Novel Synthetic Biologics, Adds Fifth U.S. Patent to Intellectual Property Portfolio
FEBRUARY 2, 2022 - CARLSBAD, CA
Amicidin-α Surgical Gel highlighted by Department of Defense – Congressionally Directed Medical Research Program (CDMRP)
OCTOBER 18, 2021 - Nature's Biopharma Dealmakers
Antimicrobials standing guard: Amicrobe engineers biologics-as-materials that are applied locally in surgery and trauma to prevent and treat life-threatening infections.
SEPTEMBER 21, 2021 - CARLSBAD, CA
Amicrobe announces kilogram-scale GMP manufacturing of Amicidins - synthetic proteins to prevent and treat life-threatening infections
AUGUST 17, 2020 - FALL ACS ONLINE CONFERENCE
Dr. Bevilacqua presents at ACS Fall 2020 Conference.
JUNE 22, 2020 - BOSTON, MA
Amicrobe awarded additional $4.6M from CARB-X to accelerate development of Amicidin-β Solution and prototype a new product, Amicidin-β/EF
MAY 28, 2020 - CARB-X WEBINAR
Dr. Bevilacqua presents at CARB-X webinar on "Preparing for an FDA Pre-IND Meeting: Planning for Success"
FEBRUARY 12, 2020 - CARLSBAD, CA
Amicrobe raises $2.5 million through convertible debt offering
NOVEMBER 7, 2019 - WASHINGTON, DC
Dr. Bevilacqua an invited speaker at the World Antimicrobial Resistance Congress
NOVEMBER 5, 2019 - SILVER SPRING, MD
Amicrobe holds pre-IND face-to-face meeting with the FDA on Amicidin-β Solution
SEPTEMBER 5, 2019 - BOSTON, MA
Dr. Bevilacqua an invited panelist at ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
AUGUST 27, 2019 - SAN DIEGO, CA
Dr. Bevilacqua gives invited presentation "Amicidin-alpha and Amicidin-beta: Amino acid block copolymers in development for prevention and treatment of infection in surgery and trauma" at the Fall 2019 American Chemical Society conference
AUGUST 20, 2019 - KISSIMMEE, FL
Amicrobe presents at the 2019 Military Health System Research Symposium
OCTOBER 18, 2018 - SILVER SPRING, MD
Amicrobe holds pre-IND face-to-face meeting with the FDA on Amicidin-α Surgical Gel
AUGUST 21, 2018 - KISSIMMEE, FL
Amicrobe presents at the 2018 Military Health System Research Symposium
AUGUST 20, 2018 - SILVER SPRING, MD
Dr. Bevilacqua an invited panelist for FDA workshop “Development of Non-Traditional Therapies for Bacterial Infections”
READ MORE
JUNE 14, 2018 - WASHINGTON, DC
Dr. Michael Bevilacqua, Amicrobe’s founder and CEO, was an invited speaker and panelist at an FDA supported meeting on the topic of developing “… Emerging Non-traditional Antibiotics”.
APRIL 24, 2018 - CARLSBAD, CA
Amicrobe, Inc., developer of novel technology for antibiotic resistance, adds safety application to intellectual property portfolio
APRIL 17, 2018 - CARLSBAD, CA
Antimicrobial innovator Amicrobe, Inc. positions managment team in anticipation of product trials
OCTOBER 24, 2017 - CARLSBAD, CA
Amicrobe, Inc. announces receipt of $2.48M award from award from CARB-X to accelerate development of Amicidin-β for treatment of life-threatening infections in surgery and trauma
bottom of page